Eli Lilly (LLY) Enterprise Value (2009 - 2026)

Eli Lilly has reported Enterprise Value for 18 years, with the latest figure at -$5.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 68.29% year-over-year to -$5.3 billion; the trailing twelve-month figure through Mar 2026 stood at -$5.3 billion (down 68.29% YoY), and the FY2025 full-year result was -$7.3 billion, down 117.39% from the prior year.
• Enterprise Value for Q1 2026 stood at -$5.3 billion, up from -$7.3 billion in the prior quarter.
• The five-year high for Enterprise Value was -$2.1 billion in Q4 2022, with the low at -$9.9 billion in Q3 2025.
• Historically, Enterprise Value has averaged -$3.7 billion across 5 years, with a median of -$3.1 billion in 2025.
• Annual changes were most pronounced in 2022 — Enterprise Value jumped 44.11% — and 2025, when it plunged 186.7%.
• Eli Lilly's Enterprise Value stood at -$2.1 billion in 2022, then sank by 35.94% to -$2.8 billion in 2023, then decreased by 17.89% to -$3.3 billion in 2024, then slumped by 117.39% to -$7.3 billion in 2025, then gained by 27.33% to -$5.3 billion in 2026.
• The last three Enterprise Value figures came in at -$5.3 billion (Q1 2026), -$7.3 billion (Q4 2025), and -$9.9 billion (Q3 2025), per Business Quant data.